Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors
Heart failure is a chronic disease that affects millions of people worldwide and is a leading cause of death. Sodium-glucose cotransporter type 2 inhibitors are a new class of drugs that have demonstrated cardiovascular benefits in patients with type 2 diabetes. The aim of the research was to gain i...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Spanish |
| Published: |
Centro Provincial de Información de Ciencias Médicas. Cienfuegos
2024-09-01
|
| Series: | Medisur |
| Subjects: | |
| Online Access: | http://medisur.sld.cu/index.php/medisur/article/view/45262 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832576805292212224 |
|---|---|
| author | Riber Fabián Donoso Noroña Nairovys Gómez Martínez Adisnay Rodríguez Plasencia |
| author_facet | Riber Fabián Donoso Noroña Nairovys Gómez Martínez Adisnay Rodríguez Plasencia |
| author_sort | Riber Fabián Donoso Noroña |
| collection | DOAJ |
| description | Heart failure is a chronic disease that affects millions of people worldwide and is a leading cause of death. Sodium-glucose cotransporter type 2 inhibitors are a new class of drugs that have demonstrated cardiovascular benefits in patients with type 2 diabetes. The aim of the research was to gain insight into the efficacy of these drugs in the treatment of heart failure. To achieve this, a systematic search was conducted in the PubMed, Embase and Cochrane Library databases from 2018 to 2023. Randomized clinical trials comparing sodium-glucose cotransporter type 2 inhibitors with placebo or standard treatment in patients with heart failure were included. Ten clinical trials were identified that met the inclusion criteria. The results showed that the treatment significantly reduced the risk of hospitalization for heart failure and cardiovascular mortality compared with placebo or standard care, and that sodium-glucose cotransporter type 2 inhibitors improved cardiac function and reduced levels of B-type natriuretic peptide, a biomarker of cardiac stress. The results of this study support the inclusion of sodium-glucose cotransporter type 2 inhibitors in the treatment of heart failure in patients with or without type 2 diabetes. Further studies are needed to evaluate the long-term safety and efficacy of sodium-glucose cotransporter type 2 inhibitors in patients with heart failure. |
| format | Article |
| id | doaj-art-08caa62d2d0240cfbf04da4cbe224235 |
| institution | Kabale University |
| issn | 1727-897X |
| language | Spanish |
| publishDate | 2024-09-01 |
| publisher | Centro Provincial de Información de Ciencias Médicas. Cienfuegos |
| record_format | Article |
| series | Medisur |
| spelling | doaj-art-08caa62d2d0240cfbf04da4cbe2242352025-01-30T21:29:03ZspaCentro Provincial de Información de Ciencias Médicas. CienfuegosMedisur1727-897X2024-09-012259829872562Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 InhibitorsRiber Fabián Donoso Noroña0Nairovys Gómez Martínez1Adisnay Rodríguez Plasencia2Universidad Regional Autónoma de Los Andes. Ambato. Ecuador.Universidad Regional Autónoma de Los Andes. Ambato. Ecuador.Universidad Regional Autónoma de Los Andes. Ambato. Ecuador.Heart failure is a chronic disease that affects millions of people worldwide and is a leading cause of death. Sodium-glucose cotransporter type 2 inhibitors are a new class of drugs that have demonstrated cardiovascular benefits in patients with type 2 diabetes. The aim of the research was to gain insight into the efficacy of these drugs in the treatment of heart failure. To achieve this, a systematic search was conducted in the PubMed, Embase and Cochrane Library databases from 2018 to 2023. Randomized clinical trials comparing sodium-glucose cotransporter type 2 inhibitors with placebo or standard treatment in patients with heart failure were included. Ten clinical trials were identified that met the inclusion criteria. The results showed that the treatment significantly reduced the risk of hospitalization for heart failure and cardiovascular mortality compared with placebo or standard care, and that sodium-glucose cotransporter type 2 inhibitors improved cardiac function and reduced levels of B-type natriuretic peptide, a biomarker of cardiac stress. The results of this study support the inclusion of sodium-glucose cotransporter type 2 inhibitors in the treatment of heart failure in patients with or without type 2 diabetes. Further studies are needed to evaluate the long-term safety and efficacy of sodium-glucose cotransporter type 2 inhibitors in patients with heart failure.http://medisur.sld.cu/index.php/medisur/article/view/45262insuficiencia cardíacainhibidores del cotransportador de sodio-glucosa de tipo 2ensayos clínicos aleatorioshospitalizaciónmortalidadsistema cardiovascularpruebas de función cardíaca |
| spellingShingle | Riber Fabián Donoso Noroña Nairovys Gómez Martínez Adisnay Rodríguez Plasencia Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors Medisur insuficiencia cardíaca inhibidores del cotransportador de sodio-glucosa de tipo 2 ensayos clínicos aleatorios hospitalización mortalidad sistema cardiovascular pruebas de función cardíaca |
| title | Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors |
| title_full | Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors |
| title_fullStr | Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors |
| title_full_unstemmed | Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors |
| title_short | Treatment of Heart Failure with Sodium-glucose Cotransporter Type 2 Inhibitors |
| title_sort | treatment of heart failure with sodium glucose cotransporter type 2 inhibitors |
| topic | insuficiencia cardíaca inhibidores del cotransportador de sodio-glucosa de tipo 2 ensayos clínicos aleatorios hospitalización mortalidad sistema cardiovascular pruebas de función cardíaca |
| url | http://medisur.sld.cu/index.php/medisur/article/view/45262 |
| work_keys_str_mv | AT riberfabiandonosonorona treatmentofheartfailurewithsodiumglucosecotransportertype2inhibitors AT nairovysgomezmartinez treatmentofheartfailurewithsodiumglucosecotransportertype2inhibitors AT adisnayrodriguezplasencia treatmentofheartfailurewithsodiumglucosecotransportertype2inhibitors |